Investigator
Weston Daniel
EVOQ THERAPEUTICS, INC. · funded by NIAID, NCATS
- Companies
- 2
- Grants
- 2
- Non-dilutive funding
- $2.0M
- First award
- Jul 15, 2022
Resolved onto their grants.
Federal awards on file.
Summed across those awards.
Latest Sep 19, 2025.
Companies from this work
Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.
- EVOQ THERAPEUTICS, INC.Momentum in another area
ImmunologyGrant-only
- EVOQ THERAPEUTICS, INC.Momentum in another area
ImmunologyGrant-only
Grant record
Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.
- R44
NanoDiscs for Immune Modulation in Celiac Disease
$1.1MSep 19, 2025NIAIDEVOQ THERAPEUTICS, INC.NIH RePORTER · 11184872 (opens the source filing in a new tab)
- R44
Novel immunotherapy against MOG antibody disease
$989kJul 15, 2022NCATSEVOQ THERAPEUTICS, INC.NIH RePORTER · 11136993 (opens the source filing in a new tab)
This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources